InvestorsHub Logo
Followers 3
Posts 1981
Boards Moderated 1
Alias Born 11/02/2016

Re: Emerald Isle post# 13423

Thursday, 12/03/2020 5:40:48 AM

Thursday, December 03, 2020 5:40:48 AM

Post# of 16445
Emerald Isle,


"First step would be to release information on the existence of a patent protected technology."


I'm sure you are aware of that June 3,2020 PR ? The company was searching months before. I wonder why we haven't gotten a partner yet ?



"NanoLogix Seeks Development & Marketing Partner for Their Sub 1-Hour COVID-19 Detection Tests

by NanoLogix | Jun 3, 2020

NanoLogix, Inc. (OTC: NNLX), an innovator in the rapid detection and identification of viruses and bacteria, is seeking a partner or partners for obtaining FDA Emergency Use Authorization, if required, and for development and marketing of their sub 1-hour COVID-19 Point of Care modified-ELISA detection test. This Rapid Viral Assay can also be configured for other viruses, such as, but not limited to, HIV, HPV, Hepatitis, MERS, and SARS-1. A Home-Test version of the COVID-19 test has the potential of 30-minute results using a nasopharyngeal swab or saliva samples.

CEO Bret Barnhizer stated: “NanoLogix does not possess the scale of production or marketing required for this essential test distribution for COVID-19. We cannot expand rapidly enough to meet the immediate need for testing. We have entered into Confidentiality Agreements with two diagnostic and financial groups in the last week for this purpose and are inviting additional interest.”

Jonathan Faro, MD, PhD., Chief Medical Officer stated: “We are extremely excited over this technology development. It is a novel approach in diagnostics that provides a solution to the inherent problems with false positives and false negatives present in those tests currently being used in the war against COVID-19.”